TriStrata/Mary Kay suit
This article was originally published in The Rose Sheet
Executive Summary
Wilmington, Del. federal court denied Mary Kay's post-trial motions to set aside jury verdict in alpha hydroxy acid patent infringement case, and entered final judgment, with interest, in TriStrata's favor, NeoStrata division reports April 5. Interest on back royalties will bring total amount of the judgment to about $41.4 mil., firm notes. Mary Kay had sought to set aside a 2005 jury verdict, which found the company infringed three TriStrata patents and required direct-seller to pay $26.4 mil. TriStrata won similar AHA patent infringement cases against Valeant Pharmaceuticals, which also failed to overturn a jury verdict (1"The Rose Sheet" March 10, 2004, In Brief)...
You may also be interested in...
Tristrata lawsuit
Valeant Pharmaceutical's motion seeking to overturn a jury verdict finding the company infringed two patents held by Tristrata Corporation and requesting a new trial is rejected by Wilmington, Del. federal court, according to parent company NeoStrata. Court also issues a permanent injunction prohibiting Valeant from the "manufacture, sale and marketing of products covered by the infringed patents." In November, the court ruled that Valeant willfully infringed the two patents, which cover the use of alpha hydroxy acids "to enhance the therapeutic effect of other substances" (1"The Rose Sheet" Dec. 1, 2003, In Brief). Patent infringement suits are still pending against other firms including Mary Kay cosmetics and BeautiControl...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.